Tag: Obesity

NIH internships, osteoarthritis, obesity tracker

Here is a look at some of the top health and medicine stories making headlines today: CANCELLED INTERNSHIP

Novo Nordisk to sell obesity drug Wegovy direct to patients at lower price

Novo Nordisk has announced that it will be offering its obesity drug Wegovy directly to patients at a

Jay Bhattacharya, Medicaid cuts, obesity in 2050

The rise of infectious diseases in pets is becoming a growing concern, mirroring the increase in human diseases.

Biocon Launches Diabetes, Obesity Management Drug In UK

New Delhi: Leading biotechnology company Biocon has recently introduced a groundbreaking product in the UK for managing diabetes

Market pressure seen as fueling too much weight loss in new obesity drugs

Eli Lilly's next-generation obesity drug, known as retatrutide, is causing unexpected outcomes in ongoing trials. Instead of struggling

Super Bowl Ad Raises Questions About Compounded V. Brand Obesity Meds

The ongoing debate surrounding the use of compounded weight loss drugs as a more affordable alternative to branded

BMI Sidelined in New Obesity Definition That Favors Health Evaluation

A group of 58 researchers have challenged the traditional definition and diagnosis of obesity, arguing that current methods

A new definition of obesity could help treat millions of people

Measuring body fat more carefully could help treat obesityHalfpoint/Getty Images Rethinking the way we define obesity could have

Experts propose ‘preclinical’ and ‘clinical’ obesity

Shifting the focus away from BMI as the sole indicator of obesity opens up a new realm of

Lilly’s Obesity Drug Zepbound To Be Key 2025 Health Cost Driver

The introduction of the anti-obesity drug Zepbound by Eli Lilly & Co. is projected to have a significant

Eli Lilly’s obesity drug Zepbound approved to treat sleep apnea in U.S.

The Food and Drug Administration (FDA) recently approved Eli Lilly's obesity drug Zepbound, also known as tirzepatide, as

U.S. adult obesity rate fell in 2023, as use of GLP-1 meds rose

The findings showed that the obesity rate in the United States decreased from 46.2% in 2021 to 45.6%